YU51294A - Upotreba aktivne supstance flupirtin za proizvodnju medikamenata za tretman neuredegenerativnih oboljenja - Google Patents

Upotreba aktivne supstance flupirtin za proizvodnju medikamenata za tretman neuredegenerativnih oboljenja

Info

Publication number
YU51294A
YU51294A YU51294A YU51294A YU51294A YU 51294 A YU51294 A YU 51294A YU 51294 A YU51294 A YU 51294A YU 51294 A YU51294 A YU 51294A YU 51294 A YU51294 A YU 51294A
Authority
YU
Yugoslavia
Prior art keywords
diseases
flupirtin
treatment
active substance
degenerative
Prior art date
Application number
YU51294A
Other languages
English (en)
Other versions
YU49215B (sh
Inventor
M. Schwarz
G. Pergande
Y. Engel
B. Nickel
H. Urlich
S. Szelenei
Original Assignee
Asta Medica Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag. filed Critical Asta Medica Ag.
Publication of YU51294A publication Critical patent/YU51294A/sh
Publication of YU49215B publication Critical patent/YU49215B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Confectionery (AREA)

Abstract

UPOTREBA AKTIVNE SUPSTANCE FLUPIRTIN ZA PROIZVODNJU MEDIKAMENATA ZA TRETMAN NEUREDEGENERATIVNIH OBOLJENJA - Pronalazak je iz oblasti farmaceutske hemije i odnosi se na upotrebu aktivne supstance Flupirtin za proizvodnju medikamenta za tretman raznih neurodegenerativnih oboljenja kao što su cerebralna ishemija, epilepticki napadi, Parkinsonova bolest, Alzheimerovo oboljenje, Chorea Huntington, multipla skleroza, amiotropicna lateralna skleroza, infektivno-indukovana i metabolitko-toksicna neurodegenerativna oboljenja, degenerativna i ishemicna oboljenja retine, traumatski indukovane povrede mozga i kičmene moždine, sindrom cerebralne prenadražljivosti, neuro-degenerativni sindromi perifernog nervnog sistema i neuroleptička analgezija.Flupirtin (Katadolon (R) je do sada primenjivan za proizvodnju analgetika sa centralnim dejstvom, ali je ovim pronalaskom utvrdeno da se isti može primenjivati za proizvodnju navedenih medikamenata pošto ima antagonističko dejstvo prema N-metil-D-aspartatu aminokiseline (NMDA).
YU51294A 1993-08-17 1994-08-15 Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja YU49215B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4327516A DE4327516A1 (de) 1993-08-17 1993-08-17 Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin

Publications (2)

Publication Number Publication Date
YU51294A true YU51294A (sh) 1998-05-15
YU49215B YU49215B (sh) 2004-11-25

Family

ID=6495312

Family Applications (1)

Application Number Title Priority Date Filing Date
YU51294A YU49215B (sh) 1993-08-17 1994-08-15 Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja

Country Status (27)

Country Link
US (1) US5721258A (sh)
EP (1) EP0716602B1 (sh)
JP (1) JPH09501664A (sh)
KR (1) KR100341952B1 (sh)
CN (1) CN1086291C (sh)
AT (1) ATE210442T1 (sh)
AU (1) AU694447B2 (sh)
BG (1) BG62430B1 (sh)
BR (1) BR9407293A (sh)
CA (1) CA2169718C (sh)
CZ (1) CZ289040B6 (sh)
DE (2) DE4327516A1 (sh)
DK (1) DK0716602T3 (sh)
EE (1) EE03204B1 (sh)
ES (1) ES2168309T3 (sh)
HR (1) HRP940464A2 (sh)
HU (1) HU227765B1 (sh)
IL (1) IL110681A (sh)
NO (1) NO309842B1 (sh)
NZ (1) NZ273292A (sh)
PT (1) PT716602E (sh)
RU (1) RU2166318C2 (sh)
SK (1) SK283330B6 (sh)
UA (1) UA43351C2 (sh)
WO (1) WO1995005175A1 (sh)
YU (1) YU49215B (sh)
ZA (1) ZA946176B (sh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
DE19625582A1 (de) * 1996-06-27 1998-01-02 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
ES2235368T3 (es) * 1997-10-27 2005-07-01 Sumitomo Pharmaceuticals Company, Limited Derivados de amida para tratar alteraciones neurodegenerativas de la retina.
AU1359801A (en) * 1999-11-05 2001-06-06 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
AU1353901A (en) * 1999-12-01 2001-06-12 Duke University Method of treating batten disease
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
DE10328260A1 (de) * 2003-06-23 2005-01-27 Schmidt, K.-G., Dr. med. Flupirtine-Präparat
CN1917876A (zh) * 2003-12-16 2007-02-21 Cns生物有限公司 方法和组合物
WO2006065204A1 (en) * 2004-12-14 2006-06-22 Astrazeneca Ab Substituted aminopyridines and uses thereof
EP1688141A1 (en) 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
US20060258708A1 (en) * 2005-05-16 2006-11-16 Andrulis Peter J Jr Method for treating Parkinson's disease and other neurological diseases
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
DE102011006425A1 (de) 2010-03-31 2011-10-06 Awd.Pharma Gmbh & Co. Kg Pharmazeutische Zubereitung und deren Verwendung
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
EP3027188A4 (en) * 2013-07-31 2017-03-01 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and flupirtine
WO2019014547A1 (en) * 2017-07-14 2019-01-17 Texas Tech University System FUNCTIONALIZED PYRIDINE CARBAMATES HAVING ENHANCED NEUROPROTECTOR ACTIVITY
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481205A (en) * 1980-09-13 1984-11-06 Degussa Aktiengesellschaft 2-Amino-3-carbethoxyamino-6-(p-fluoro-benzylamino)-pyridine-maleate
DE3369315D1 (en) * 1982-10-27 1987-02-26 Degussa Derivatives of 2-amino-3-acylamino-6-benzylamino pyridine with an anti-epileptic activity
DE3337593A1 (de) * 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
NO860825L (no) * 1985-03-23 1986-09-24 Degussa Fremgangsmaate til fremstilling av 2-amino-3-nitro-6-(4-fluor-benzylamino)-pyridin samt 2-amino-3-karbetoksyamino-6-(4-fluor-benzylamino)-pyridin.
IN172468B (sh) * 1990-07-14 1993-08-14 Asta Medica Ag

Also Published As

Publication number Publication date
RU2166318C2 (ru) 2001-05-10
NZ273292A (en) 1999-09-29
CN1129399A (zh) 1996-08-21
HUT75650A (en) 1997-05-28
DE4327516A1 (de) 1995-02-23
CA2169718A1 (en) 1995-02-23
EE03204B1 (et) 1999-08-16
BG62430B1 (bg) 1999-11-30
BG100356A (bg) 1996-07-31
ES2168309T3 (es) 2002-06-16
AU7652894A (en) 1995-03-14
SK283330B6 (sk) 2003-06-03
YU49215B (sh) 2004-11-25
HU227765B1 (en) 2012-02-28
KR960703591A (ko) 1996-08-31
ZA946176B (en) 1995-03-20
BR9407293A (pt) 1996-10-01
JPH09501664A (ja) 1997-02-18
CZ46596A3 (en) 1996-05-15
DK0716602T3 (da) 2002-03-25
SK21496A3 (en) 1997-01-08
HU9600355D0 (en) 1996-04-29
PT716602E (pt) 2002-05-31
CA2169718C (en) 2002-11-12
US5721258A (en) 1998-02-24
IL110681A (en) 1999-08-17
KR100341952B1 (ko) 2003-04-11
NO960607L (no) 1996-02-15
UA43351C2 (uk) 2001-12-17
EP0716602A1 (en) 1996-06-19
DE69429435D1 (de) 2002-01-24
IL110681A0 (en) 1994-11-11
CZ289040B6 (cs) 2001-10-17
WO1995005175A1 (en) 1995-02-23
HRP940464A2 (en) 1997-06-30
DE69429435T2 (de) 2002-06-13
NO309842B1 (no) 2001-04-09
CN1086291C (zh) 2002-06-19
AU694447B2 (en) 1998-07-23
ATE210442T1 (de) 2001-12-15
NO960607D0 (no) 1996-02-15
EP0716602B1 (en) 2001-12-12

Similar Documents

Publication Publication Date Title
YU51294A (sh) Upotreba aktivne supstance flupirtin za proizvodnju medikamenata za tretman neuredegenerativnih oboljenja
NZ276892A (en) Quinoxalinedione derivatives, preparation and use in pharmaceutical compositions thereof
AR015820A1 (es) Particulas de budesonida, composicion farmaceutica, uso de dichas particulas para la fabricacion de medicamentos, metodo para el tratamiento de untrastorno respiratorio y proceso para la preparacion de las particulas
FI946005A (fi) Glysiinireseptoriantagonisteja ja niiden käyttö
BRPI9807848B8 (pt) compostos de arilsulfonamidas e análogos, bem como composição farmacêutica e uso dos mesmos.
TW429152B (en) A tretinoin aqueous gel composition for therapeutic topical administration to the skin
ATE144704T1 (de) Mittel zur topischen verabreichung von arzneiwirkstoffen
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
EE04938B1 (et) Orto-asendatud antraniilhappeamiidid ja nende kasutamine ravimitena
ES2187062T3 (es) Composiciones farmaceuticas que contienen proteina plasmatica.
NL990012I1 (nl) Geneesmiddelen die salmeterol en fluticason bevatten.
ITMI911299A1 (it) Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
DE59510358D1 (de) Pharmazeutische Zusammensetzung
FR2351665A1 (fr) Procede de purification de preparations possedant notamment une activite interferon, preparations purifiees ainsi obtenues et leur application en tant que medicament
ES2061989T3 (es) Uso de esteres alquilicos del acido piroglutamico para la fabricacion de un medicamento para el tratamiento de la ictiosis.
JP2022058511A5 (sh)
RU96105707A (ru) Лекарственное средство для лечения дегенеративных заболеваний нервной системы
FR2647677B1 (fr) Nouvelles micro-proteines, procede de preparation et application a titre de medicaments de ces nouvelles micro-proteines
YU48084B (sh) Postupak za pravljenje prečišćenih rastvora albumina
ATE326947T1 (de) Thixotropes nasenspray
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
FR2452286A1 (fr) Acides phosphatidiques utilisables pour le traitement des desordres de la conscience et des desordres de la perception et des mouvements
KR960003721A (ko) 하나 이상의 RXRs 특이성 리간드 및 하나 이상의 RAR-α 특이성 리간드의 상승 혼합물 기재 신규 조성물, 및 그의 용도
TH13285EX (th) สารประกอบที่ใช้บำบัดโรคที่เกี่ยวกับการเสื่อมของประสาท
ES2059963T3 (es) Uso de 2',4',6'-trimetoxi-4-(pirrolidinil) butirofenona para el tratamiento topico de enfermedades troficas.